During the last trading session, GeoVax Labs (GOVX) stock was increasing at a sharp speed along with showing active volume and positive change. Such changes could be caused by the latest news from the company that GeoVax has entered into an Assignment and License Agreement with PNP Therapeutics, that grants GeoVax exclusive rights to develop and commercialize Gedeptin®, a novel patented product for the treatment of solid tumors. The total market capitalization of the company is 26.45M. The License provides exclusive worldwide rights to key intellectual property, including Gedeptin patents, know-how, regulatory filings, clinical materials, and trademarks. The Gedeptin technology was developed with funding support from the National Cancer Institute of the National Institutes of Health. The License also grants GeoVax the right to expand the use of Gedeptin to all human diseases and/or conditions including, but not limited to, other cancers.
- Farmmi (FAMI) Stock Jumps 31% During The Week: It Wins Additional Multi-Product Sales Win; Exporting To Israel
- Regis (RGS) Stock Surges Over 19% Amid Latest News Released This Week: Will This Stock Soar Soon?